foxm1 and pd-l1 in cdk4/6-mek resistance in nerve tumors | oncotarget
Published 6 hours ago • 8 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:54
cell cycle inhibitors - cdk4/6 inhibitors
-
4:15
pathologists and pd-l1
-
2:07
dr ma on questions regarding treatment sequencing in cdk4/6 inhibitor–resistant breast cancer
-
6:11
hr metastatic breast cancer: upfront cdk4/6 inhibition
-
8:28
cdk4/6 inhibition in breast cancer
-
26:01
the main causes of cancer & how to prevent it | dr. jason fung
-
6:08
pd-1, pd-l1 role in immune system inhibition
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
1:06
dr. finn on the potential of cdk inhibition
-
1:41
dr. harold j. burstein on cdk4/cdk6 inhibitor abemaciclib in breast cancer
-
3:00
regulation of pd-l1 in cutaneous lymphoma by mirnas
-
3:27
metastatic breast cancer: cdk4/6 inhibitors
-
3:27
metastatic breast cancer: cdk4/6 inhibitors
-
1:47
dr. siefker-radtke on pd-l1 as a biomarker in bladder cancer
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
8:55
cdk4/6 inhibitors in hr metastatic breast cancer
-
4:53
the role of immunotherapy in cancer treatment (pd-l1 overview)
-
21:58
pd-l1/tils/tmb in immunotherapy
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
59:36
mek inhibitors and nf1-associated tumors: molecular mechanisms and targeted approaches
-
2:13
mnsclc with both pd-l1 and an actionable mutation
-
4:00
cancer immunotherapy - pd-1 and pd-l1